About this trial
Sepsis is defined as a dysregulated host response to infection . Despite ongoing efforts, both the incidence and mortality of sepsis have demonstrated limited reductions over the past years,There are several biomarkers that have already been studied for the early diagnosis of sepsis. Some of these markers can be used in risk prediction and monitoring the outcome of sepsis .
Some of these markers as procalcitonin and CD14, are costly and not feasible options for low- and middle-income countries . While other biomarkers are feasible and accessible to be evaluated as Triglyceride\\glucose index (TyG) , Relative Distributive Width of red blood corpuscles to albumin ratio (RAR), C-reactive protein,Neutrophile \\Lympocyte ratio and serum lactate levels .
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
patients diagnosed by hematological disease
patients refused to participate in the research
patients less than 18 years
Trial population
To evaluate the role of various laboratory biomarkers ( TyG , RAR , CAR, N\\L ratio, CRP, Serum lactate )in prediction of sepsis outcome
Trial design
Case-control
Prospective
Treatments tested in this trial
Triglyceride glucose index
Diagnostic testTo evaluate the role of various laboratory biomarkers ( TyG , RAR , CAR, N\\L ratio, CRP, Serum lactate )in prediction of sepsis outcome.
Treatment groups
Trial outcomes
Primary outcomes
Mortality Outcome Measure
Number of Participants whom will be diagnosed with sepsis and will be admitted in the ICU
Sponsors and contacts
Click on the lead sponsor to view all of their trials.